Last reviewed · How we verify
Insulin degludec, 100U/ml
Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin degludec, 100U/ml |
|---|---|
| Also known as | Tresiba |
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin degludec is a recombinant human insulin analog engineered with an extended half-life through multi-hexamer formation, allowing once-daily dosing. It binds to the insulin receptor on muscle and adipose tissue to facilitate glucose uptake and storage, and simultaneously inhibits gluconeogenesis and glycogenolysis in the liver. This results in improved glycemic control with a lower risk of hypoglycemia compared to older basal insulins due to its ultra-long duration of action and stable pharmacokinetic profile.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (PHASE3)
- Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (PHASE4)
- A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (PHASE4)
- A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin degludec, 100U/ml CI brief — competitive landscape report
- Insulin degludec, 100U/ml updates RSS · CI watch RSS
- Sanofi portfolio CI